The study involved a total of 5380 patients with type 2 diabetes and an acute coronary syndrome event in the previous 15–90 days. Patients were randomised to alogliptin (n=2701) or placebo (n=2679) and followed up for a median of 533 days.
The prespecified exploratory extended MACE endpoint was all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, urgent revascularisation due to unstable angina, and hospital admission for heart failure. Hospital admission for heart failure was the first event in 85 (3.1%) patients taking alogliptin compared with 79 (2.9%) taking placebo (HR 1.07, 95% CI 0.79–1.46).
A related editorial discusses the findings on this study in the context of a previous study (SAVOUR-TIMI 53) which had reported a 27% increase in hospital admissions for heart failure in patients randomised to receive saxagliptin.